
Vaxcyte rose 31.1% from $48.34 to $63.37, ahead of the S&P 500's +13.3%. Its worst day was May 7 (−9.8%), and its low came Dec 17 at $43.06.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Vaxcyte closed at its lowest level of the year, 10.9% below where the year started.
−1.4% · S&P 500 −1.1%
EPS of $-1.80 missed the $-1.49 estimate on $0.00 revenue.
+2.8% · S&P 500 +0.8%
Story events cover the past 12 months · Times ET
EPS of $-2.30 missed the $-1.79 estimate on $0.00 revenue (est. $12.5M).
−9.8%, the year's worst day · S&P 500 −0.3%
EPS of $-1.97 beat the $-1.97 estimate on $0.00 revenue (est. $12.5M).
+5.3% · S&P 500 −0.2%
Vaxcyte closed at its highest level of the year, 52.7% above where the year started.
+30.7%, the year's best day, on 15M shares, the year's heaviest volume · S&P 500 +0.7%
EPS of $-1.99 beat the $-2.06 estimate on $0.00 revenue.
−5.7% · S&P 500 −4.4%
Where it ended: a close of $63.37 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $-1.92).
Nothing in the past 12 months.
All PCVX dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PCVX and SPY from Benzinga historical bars. Not investment advice.